The two most exciting events dealing with Alzheimer’s that have happened this year include:
- The U.S. Food and Drug Administration (FDA) granted traditional approval of Donanemab, sold under the brand name Kisunla, for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques.
A valuable Alzheimer’s disease diagnostic tool will now be more accessible across the country thanks to a policy change by the Centers for Medicare & Medicaid Services (CMS). CMS will expand coverage of brain amyloid positron emission tomography (PET) imaging for the diagnosis of Alzheimer’s disease. In issuing its new policy, CMS said the specific details of the coverage will be made by the Medicare Administrative Contractors (MACs).
Please continue to donate so that more progress can be made to eradicate this deadly illness.
Donation page – Team Red Hot Annie - https://act.alz.org/site/TR/Walk2024/DC-NationalCapitalArea?team_id=872426&pg=team&fr_id=17512
My Progress
Thank you for helping advance Alzheimer's support, care and research.
500
I have raised
100
My Goal
My Achievements
Self-Donor
Fundraiser
T-shirt
Champion
Storyteller
Mobile Master